ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1822

Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans

Gabriela Schmajuk1, Yinghui Miao2, Jinoos Yazdany3, Mary Margaretten4 and Michael Steinman2, 1Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, 2Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, 3Medicine, University of California, San Francisco, San Francisco, CA, 4Rheumatology, University of California, San Francisco, San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: methotrexate (MTX), quality of care and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: The National Quality Forum recently endorsed a controversial quality measure that assesses liver toxicity monitoring for patients receiving oral methotrexate (MTX).  Using national data from the Veterans Health Administration (VHA), we assessed the frequency of liver function testing (LFT) and rates of MTX discontinuation after minimally elevated LFTs among patients taking oral MTX.

Methods: We created a national cohort of incident MTX users ≥ age 65 using linked pharmacy and laboratory data from the VHA during fiscal years 2007-2008. Patients were included if they had ≥ 28-day supply of MTX dispensed and use of VHA services for a minimum of 180 days prior and 90 days after the index MTX prescription.  Patients were excluded if they had any diagnosis of inflammatory bowel disease (ICD-9 codes 555.x, 556.x) or if they had evidence of having obtained care outside of the VHA (patients with any medical encounter billed to Medicare during the study period were removed from the sample). We defined performance on the MTX liver toxicity monitoring quality measure through 2 methods (Table). Using the value of the first abnormal LFT after the index MTX prescription, we assessed rates of MTX discontinuation (defined as lack of MTX dispensed for ≥ 90 days after the anticipated refill date).

Results: 899 new users of MTX met inclusion and exclusion criteria for the study. 97% were male, mean age was 71 years (SD 6.3), and mean follow-up period was 267 days (SD 133). Mean MTX dose received was 11.4 mg weekly (SD 5.1). Performance on the quality measure is described in the Table.  148 (16.5%) patients did not have any LFT testing after MTX was initiated. 136/899 (15%) patients had any abnormality of AST or ALT during the follow-up period; 49/899 (5%) had an elevation of ≥ 1.5 x upper limit of normal (ULN). MTX was discontinued in 28/87 (32%) subjects with LFT elevations < 1.5 x ULN and 27/49 (55%) subjects with elevations ≥ 1.5 x ULN. Compared to patients with no LFT elevations during the follow-up period, patients with LFT elevations < 1.5 x ULN had 1.4 greater odds (95% CI 1.1, 1.8) of stopping MTX.

Conclusion:  Despite many MTX users not receiving liver toxicity monitoring with the frequency intended by the National Quality Forum quality measure, one third of patients with mild LFT elevations may be having their MTX stopped unnecessarily.  These findings suggest that there may be unintended negative consequences to a policy that encourages more frequent liver toxicity monitoring.

Table. Performance on methotrexate liver toxicity monitoring quality measure in a national cohort of veterans

 

Definition

Description

Performance in national veteran incident user cohort

NQF technical specification

Proportion of patients in the population who were prescribed at least a 6-month supply of methotrexate during the measurement year that received a liver function test in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.

77%

Rolling interval method (Agnew-Blais 2009)

Mean of the “percent adherence” for each individual, calculated as the proportion of intervals (ranging in duration from 0-12 weeks) during the time when a patient was exposed to methotrexate in which a liver function test was documented.

65%

 


Disclosure:

G. Schmajuk,
None;

Y. Miao,
None;

J. Yazdany,
None;

M. Margaretten,
None;

M. Steinman,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/liver-toxicity-monitoring-and-its-impact-on-methotrexate-discontinuation-in-a-national-cohort-of-veterans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.